Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 522

Related Citations for PubMed (Select 19779203)

1.

Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening.

Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Habbema JD, Kuipers EJ.

J Natl Cancer Inst. 2009 Oct 21;101(20):1412-22. doi: 10.1093/jnci/djp319. Epub 2009 Sep 24.

2.

Cost-effectiveness of colonoscopy in screening for colorectal cancer.

Sonnenberg A, Delcò F, Inadomi JM.

Ann Intern Med. 2000 Oct 17;133(8):573-84.

PMID:
11033584
3.

Cost-effectiveness of screening for colorectal cancer in the general population.

Frazier AL, Colditz GA, Fuchs CS, Kuntz KM.

JAMA. 2000 Oct 18;284(15):1954-61.

PMID:
11035892
4.

Cost effectiveness and projected national impact of colorectal cancer screening in France.

Hassan C, Benamouzig R, Spada C, Ponchon T, Zullo A, Saurin JC, Costamagna G.

Endoscopy. 2011 Sep;43(9):780-93. doi: 10.1055/s-0030-1256409. Epub 2011 May 27.

PMID:
21623557
5.

Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population.

Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, Savarino JE, van Ballegooijen M, Kuntz KM, Zauber AG.

J Natl Cancer Inst. 2010 Aug 18;102(16):1238-52. doi: 10.1093/jnci/djq242. Epub 2010 Jul 27.

6.
7.

Estimates of costs and effects of screening for colorectal cancer in the United States.

Byers T, Gorsky R.

Cancer. 1992 Sep 1;70(5 Suppl):1288-95.

PMID:
1387342
8.

Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies.

Sharaf RN, Ladabaum U.

Am J Gastroenterol. 2013 Jan;108(1):120-32. doi: 10.1038/ajg.2012.380. Epub 2012 Dec 18.

PMID:
23247579
9.

Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia.

Tsoi KK, Ng SS, Leung MC, Sung JJ.

Aliment Pharmacol Ther. 2008 Aug 1;28(3):353-63. doi: 10.1111/j.1365-2036.2008.03726.x.

PMID:
18638075
10.

Colorectal cancer screening comparing no screening, immunochemical and guaiac fecal occult blood tests: a cost-effectiveness analysis.

van Rossum LG, van Rijn AF, Verbeek AL, van Oijen MG, Laheij RJ, Fockens P, Jansen JB, Adang EM, Dekker E.

Int J Cancer. 2011 Apr 15;128(8):1908-17. doi: 10.1002/ijc.25530.

PMID:
20589677
11.

Endoscopic colorectal cancer screening: a cost-saving analysis.

Loeve F, Brown ML, Boer R, van Ballegooijen M, van Oortmarssen GJ, Habbema JD.

J Natl Cancer Inst. 2000 Apr 5;92(7):557-63.

12.

Cost-effectiveness of population-based screening for colorectal cancer: a comparison of guaiac-based faecal occult blood testing, faecal immunochemical testing and flexible sigmoidoscopy.

Sharp L, Tilson L, Whyte S, O'Ceilleachair A, Walsh C, Usher C, Tappenden P, Chilcott J, Staines A, Barry M, Comber H.

Br J Cancer. 2012 Feb 28;106(5):805-16. doi: 10.1038/bjc.2011.580. Epub 2012 Feb 16.

13.

Comparative economic evaluation of data from the ACRIN National CT Colonography Trial with three cancer intervention and surveillance modeling network microsimulations.

Vanness DJ, Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, Gareen IF, Herman BA, Kuntz KM, Zauber AG, van Ballegooijen M, Feuer EJ, Chen MH, Johnson CD.

Radiology. 2011 Nov;261(2):487-98. doi: 10.1148/radiol.11102411. Epub 2011 Aug 3.

14.

Cost-effectiveness modeling of colorectal cancer: computed tomography colonography vs colonoscopy or fecal occult blood tests.

Lucidarme O, Cadi M, Berger G, Taieb J, Poynard T, Grenier P, Beresniak A.

Eur J Radiol. 2012 Jul;81(7):1413-9. doi: 10.1016/j.ejrad.2011.03.027. Epub 2011 Mar 27.

PMID:
21444171
15.

Cutting cost and increasing access to colorectal cancer screening: another approach to following the guidelines.

Fisher JA, Fikry C, Troxel AB.

Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):108-13. Review.

16.

Fecal occult blood testing when colonoscopy capacity is limited.

Wilschut JA, Habbema JD, van Leerdam ME, Hol L, Lansdorp-Vogelaar I, Kuipers EJ, van Ballegooijen M.

J Natl Cancer Inst. 2011 Dec 7;103(23):1741-51. doi: 10.1093/jnci/djr385. Epub 2011 Nov 9.

17.

Cost identification of Nordic FLIRI, Nordic FLOX, XELIRI and XELOX in first-line treatment of advanced colorectal cancer in Sweden -- a clinical practice model approach.

Pettersson K, Carlsson G, Holmberg C, Sporrong SK.

Acta Oncol. 2012 Sep;51(7):840-8. doi: 10.3109/0284186X.2012.713507. Epub 2012 Aug 31.

PMID:
22937953
18.

The cost-effectiveness of screening for colorectal cancer.

Telford JJ, Levy AR, Sambrook JC, Zou D, Enns RA.

CMAJ. 2010 Sep 7;182(12):1307-13. doi: 10.1503/cmaj.090845. Epub 2010 Jul 12.

19.

Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis.

Ladabaum U, Chopra CL, Huang G, Scheiman JM, Chernew ME, Fendrick AM.

Ann Intern Med. 2001 Nov 6;135(9):769-81.

PMID:
11694102
20.

Screening for colorectal cancer: the cost to find an advanced adenoma.

McGrath JS, Ponich TP, Gregor JC.

Am J Gastroenterol. 2002 Nov;97(11):2902-7.

PMID:
12425566
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk